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• In mammals, pregnancy complications can trigger an embryonic or fetal origin of 1 
cardiac dysfunction. However, underlying mechanisms remain uncertain because the 2 
partial contributions of the challenge on the mother, placenta or offspring are difficult 3 
to disentangle. 4 
 5 
• The avian embryo permits isolation of the direct effects of suboptimal conditions during 6 
development on the cardiac function of the offspring, independent of additional effects 7 
on the mother and/or the placenta.   8 
 9 
• Therefore, the objectives of this work were to adapt the isolated Langendorff technique 10 
using the chicken embryo to study the physiology of the developing heart. 11 
 12 
•  Here, we introduce the novel technology and show the utility of the technique exploring 13 
cardioprotective roles of H2S in the chicken embryo heart. This work lays the 14 
foundation to study the direct effects of H2S therapy on the embryonic heart 15 















This study adapted the isolated Langendorff preparation to study the chicken embryo heart in 17 
response to ischaemia-reperfusion (IR) injury.  The utility of the technique was tested by 18 
investigating cardioprotective effects of hydrogen sulphide (H2S) and underlying mechanisms. 19 
Embryonic hearts (19 out of 21 days of incubation) mounted on a Langendorff preparation 20 
were exposed to IR (30 min ischaemia) after 4 treatments administered randomly, all as a 1mM 21 
bolus, into the perfusate: saline vehicle (control); sodium hydrogen sulphide (NaHS); NaHS 22 
plus glibenclamide, an antagonist of KATP opening (NaHS Glib), and Glib alone (Glib). 23 
Relative to controls, NaHS treatment improved cardiac function after ischaemia (mean±SD for 24 
under the curve, AUC, for left ventricular developed pressure, LVDP: 25 
1767.3±929.5 vs. 492.7±308.1; myocardial contractility, dP/dTmax: 2748.9±1514.9 vs. 763.7 26 
±433.1) and decreased infarct size (22.7± 8.0 vs. 43.9±4.2%) and cardiac damage (% change 27 
in creatinine kinase,  49.3±41.3 vs. 214.6 ±155.1; all P<0.05).  Beneficial effects of NaHS were 28 
blocked by Glib. Glib alone had no effects. NaHS increased CFR during baseline (mean±SD 29 
for AUC: 134.3± 91.6 vs. 92.2±35.8) and post I/R (1467± 529.5 vs. 748.0±222.1; both P<0.05).  30 
However, this effect was not prevented by Glib. Therefore, the chicken embryo heart is 31 
amenable for study via the Langendorff preparation under basal conditions and during IR. The 32 
data show that H2S confers embryonic cardiac protection via opening of myocardial KATP 33 
channels and not via increasing CFR. H2S may prove a useful therapeutic agent to protect the 34 






Complications during mammalian pregnancy, such as gestational diabetes, maternal smoking, 36 
pregnancy at high altitude or preeclampsia can trigger a fetal origin of heart disease (Fowden 37 
et al. 2006). However, underlying mechanisms have proven difficult to isolate because 38 
suboptimal conditions during pregnancy often affect the mother, the placenta as well as the 39 
developing offspring.  In this regard, oviparous species, like the chicken, offer many 40 
advantages.  Embryonic development occurs in the absence of either a mother or a placenta, 41 
nutrition is fixed within the egg, there is no need to control for within-litter variation or for 42 
effects on lactation, and many milestones of cardiac development are similar to humans (Itani 43 
et al. 2018).  Therefore, the chicken embryo is ideally placed to isolate direct effects of adverse 44 
developmental conditions and of therapy on an early origin of heart disease.  Therefore, the 45 
objectives of this work were to adapt the isolated Langendorff technique using the chicken 46 
embryo to study the physiology of the developing heart under basal conditions during 47 
ischaemia-reperfusion (IR) injury. The validity of the technique was tested by investigating 48 
potential cardioprotective agents against IR and underlying physiological mechanisms. 49 
 
Growing evidence suggests that H2S is vital to cardiovascular health (Shen et al. 2015).  For 50 
instance, clinical studies report that a decrease in endogenous H2S levels is linked to age-related 51 
cardiovascular pathology (Jiang et al. 2005; Polhemus et al. 2014; Perridon et al. 2016).  52 
Moreover, work in animal models shows that supplementation with an exogenous H2S donor 53 
protects the adult heart from ischaemic reperfusion (IR) injury (Johansen et al. 2006). 54 
However, whether H2S confers protection in the developing heart before birth remains 55 






Mechanisms underlying cardiac protection by H2S may include an increase in coronary blood 57 
flow enhancing coronary reserve due to its vasodilator actions (Bhatia, 2005) and/or action on 58 
myocardial KATP channels (Shen et al. 2015).   Under normal physiological conditions in the 59 
adult heart, KATP channels are closed (Lu et al. 2008).  In response to a decrease in the 60 
ATP:ADP ratio, as experienced during an ischaemic challenge, myocardial KATP open. This 61 
preserves cardiac health via limiting calcium influx and energy expenditure (Lederer et al. 62 
1989; Burke et al. 2008). Mutations in cardiac KATP channels have been identified in patients 63 
with dilated cardiomyopathy (Bienengraeber et al. 2004).  Genetic and pharmacological 64 
disruption of KATP channels impairs recovery following IR and negates the beneficial effects 65 
of ischaemic preconditioning (Suzuki et al. 2001; Gumina et al. 2003; Kane et al. 2006).  66 
Conversely, KATP overexpression confers resistance to ischaemic injury (Du et al. 2006).   67 
 
Episodes of IR can also present in utero for a range of reasons.  These include periods of 68 
increased uteroplacental vascular resistance, such as during preeclampsia, or during 69 
compression of the umbilical cord in late gestation, as in complicated labour and delivery 70 
(Morrison, 2008; Giussani, 2016).  A recent review by Bennet (2017) shows clearly that the 71 
preterm sheep fetus is remarkabky tolerant to episodes of ischaemia produced by complete 72 
occlusion of the umbilical cord, even those lasting for periods longer than 20 minutes.  Despite 73 
the fetal heart being more resistant to ischaemia compared to the adult heart, insufficient 74 
oxygen supply to developing organs can have detrimental and long-term effects, particularly 75 
in metabolically active tissues, such as the fetal heart in late gestation (Li et al. 2003). Growing 76 
evidence derived from human clinical studies as well as from animal models links suboptimal 77 
oxygenation during fetal development with increased cardiac susceptibility in the neonatal 78 
period, as well as increased cardiac risk in the adult offspring (Paterson & Zhang, 2010; 79 





targets and interventions to protect the developing heart against IR injury.  Here, we tested the 81 
hypothesis that H2S confers protection against IR injury in the embryonic heart via opening of 82 
KATP channels and not via increasing coronary flow. This work lays the foundation to study the 83 
direct effects of H2S therapy on the embryonic heart independent of effects on the mother and 84 




Ethical Approval  
All animal procedures conform with the guidelines from Directive 2010/63/EU of the European 86 
Parliament on the protection of animals used for scientific purposes.  This research was 87 
approved under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 88 
following ethical review by the University of Cambridge Animal Welfare and Ethical Review 89 
Board (AWERB). 90 
Data, Materials and Code Disclosure Statement  
The data discussed herein can be obtained from the corresponding author upon request.  91 
Animals  
All experiments were performed in the same experimental season.  Fertilized Bovans Brown 92 
eggs (Medeggs, Norfolk, UK) were weighed and incubated from day 1 under controlled 93 
normoxic conditions (21% O2, 37.9°C, 45% humidity, 12:12 hr light:dark cycle, automatic 94 
rotation every hour, Masalles incubator Mod-75A with electronic servo-controlled humidity 95 





humidity, and temperature inside the incubators were continuously monitored (DD103 DrDAQ 97 
Oxygen Sensor, Pico Technology, St. Neots, UK).  98 
Embryonic Langendorff Heart Preparation 
On day 19 (term is 21 days) of incubation, chicks were humanely killed by cervical transection. 99 
The heart was rapidly excised and immediately placed in ice-cold Krebs–Henseleit Buffer 100 
(KHB, NaCl:120 mM, KCl:4.7 mM, MgSO2.7H2O:1.2 mM, KH2PO4:1.2 mM, NaHCO3:25 101 
mM, glucose:10 mM, CaCl2.2H2O:1.3 mM), then mounted onto the Langendorff apparatus 102 
which was maintained at constant physiological temperature (Figure 1). Great care needs to be 103 
taken when mounting the heart as the chicken embyo aorta is very fragile. Using an aortic 104 
cannula, which was made from a 19 G needle,  this preparation achieves retrograde perfusion 105 
of the isolated heart (Niu et al.  2013).  The perfusing solution was KHB (40°C, gassed with 106 
O2:CO2, 95:5%) delivered at a constant pressure of 40 cm H2O and filtered through a 5 μm 107 
cellulose nitrate filter (Millipore, Bedford, MA, USA). A small incision in the left atrium was 108 
made to allow a small, flexible non-elastic balloon made from cling film to be inserted into the 109 
left ventricle. The balloon contained distilled water and was connected to a rigid water-filled 110 
catheter, and then to a calibrated pressure transducer (Argon Medical Devices, Plano, TX, 111 
USA).  Therefore, this set up allowed continuous monitoring of cardiac function. To obtain a 112 
left ventricular end diastolic pressure (LVEDP) of 5-10 mmHg, a 100-μL Hamilton syringe 113 
was used to adjust the balloon volume to 30 μL (Giussani et al. 2012; Niu et al. 2013).  114 
Basal Function 
Isolated hearts were given 15 min to stabilise on the preparation, then baseline functional 115 
recordings were made using an IDEEQ data acquisition system (version 0-2.5.0, Maastricht, 116 





developed pressure (LVDP), LV end diastolic pressure (LVEDP), the maximum first derivative 118 
(dP/dtmax) and minimum first derivative (dP/dtmin) of left ventricular pressure, the contractility 119 
index (dP/dtmax normalised to mean pressure at the point of dP/dtmax), and Tau (the 120 
isovolumetric relaxation time constant). In addition, coronary flow rate (CFR) was determined 121 
gravimetrically via measuring the volume of perfusate effluent over time (Niu et al. 2013).  122 
Drug Administration 
Hearts received treatment 10 min before ischaemia according to one of four randomly-allocated 123 
groups: Control (buffer), Control+ NaHS (Sodium hydrogen sulphide, a H2S donor, Hosoki et 124 
al. 1997), Control + Glib (Glibenclamide, a non-selective inhibitor of KATP opening, Ripoll et 125 
al. 1993) or Control +NaHS+Glib. All drugs were given as a single bolus at 1mM concentration 126 
dissolved in 0.5 ml of buffer vehicle, 10 minutes prior to ischaemia. The dose of NaHS 127 
administration was adopted from our own pilot experiments which showed indices of cardiac 128 
protection of NaHS with this dose and regimen of administration. The rationale for using 1 mM 129 
Glib was that this would stoichiometrically balance with the NaHS dose.  All drugs were 130 
obtained from Sigma-Aldrich, Dorset, UK. Cardiac function and CFR were measured 131 
following treatment, during and after IR. 132 
Ischaemia/Reperfusion (IR) Protocol  
10 minutes after treatment, half an hour of global ischaemia was induced by shutting off the 133 
supply of perfusate (Figure 1). Cardiac function was analysed at 10 min intervals during 134 
baseline and ischaemia, and at 0 min, 5 min, 15 min, 30 min and 60 min reperfusion time. 135 
Coronary flow rate was analysed at 10 min intervals during baseline and ischaemia, and at 0 136 
min, 15 min, 30 min and 60 min reperfusion time. Perfusate samples were taken during baseline 137 





Infarct Size Analysis 
Following 2h of reperfusion, the heart was taken off the preparation. After recording of the 139 
heart weight, the heart was cooled for 10 min at -20°C because this allowed the tissue to be 140 
sliced more easily in a semi-frozen state. The heart was then sliced transversely into 5 x 1.5 141 
mm-thick sections using a custom made slicer (Figure 2A). Mid cardiac slices (Slice 3) were 142 
incubated with 0.1% triphenyltetrazolium chloride dissolved in a phosphate buffer [mixture of 143 
Na2HPO4 (77.4%) and NaH2PO4 (22.6%)] for 20 min at 37 °C. Mid cardiac slices were then 144 
scanned (Scanjet 300, Hewlett Packard, Cambridge, UK) and the % infarct size from this 145 
section was determined using Image J software (version 1.52, National Institute of Health, 146 
Bethesda, MD, USA; Figure 2B).  To quantify the infarct size, the colour threshold function in 147 
ImageJ was used to filter the background and select the infarcted area (Figure 2B-F). ImageJ 148 
then reported the number of pixels in the infarcted area and the total slice area. Infacrt size was 149 
calculated as a percentage by dividing the number of pixels representing the infarcted area by 150 
the number of pixels representing the total slice area. 151 
 
Perfusate analysis 
Coronary effluent samples (2 mL) were immediately frozen in liquid nitrogen and stored at 152 
−80°C until analysis. Perfusate creatine kinase (CK) activity was analysed using a bichromatic 153 
coupled enzyme reaction assay (Siemens Dimension RxL analyser, Malvern, PA), while lactate 154 
dehydrogenase (LDH) activity was assessed using a colorimetric assay (Siemens Dimension 155 
RxL analyser, Malvern, PA). Activity of these enzymes are established markers of cardiac 156 






Statistical analysis  
Appropriate power calculations derived from previous data sets were performed to determine 158 
the minimum sample size required to achieve statistical significance set at P<0.05 (Mulder et 159 
al. 2002). Scientists measuring outcomes were blinded to treatments.  All data are expressed 160 
as mean±SD. Comparisons were assessed for statistical significance using two- or three-way 161 
ANOVA. If interactions between main factors were significant, the Tukey pot hoc test was 162 
used to isolate differences. For all comparisons, statistical significance was taken when P<0.05. 163 
 
RESULTS 
Biometry and Basal Cardiac Function 
Body weight, heart weight and relative heart weight of chicken embryos showed no significant 164 
difference between experimental groups (Table 1). Baseline cardiac function did not differ 165 
significantly between experimental groups (Table 1).  Administration of the drugs or vehicle 166 
had no significant impact on heart rate, or indices of systolic and diastolic function prior to 167 
ischaemia, with the exception of coronary flow rate (Table 2).  Coronary flow rate increased 168 
after NaHS with or without Glib during baseline conditions prior to ischaemia (Table 2, NaHS 169 









Cardiac Function Following Ischaemia 
In control embryos, ischaemia led to significant depression of chronotopic (HR) and inotropic 172 
(LVDP) function (Figure 3A-D), as well as cardiac contractility (dP/dtmax) and relaxability 173 
(dP/dtmin) during reperfusion (Figure 4A-D). Administration of NaHS prior to ischaemia 174 
restored cardiac function towards basal levels post IR (Figure 3A-D and 4A-D), with the AUC 175 
of cardiac recovery significantly greater for all four cardiac functional variables in Con+NaHS 176 
vs. controls (Figures 3B and 3D, 4B and 4D). When NaHS was co-administered with Glib, 177 
there was no longer any cardioprotective effects (Figures 3A-D and 4A-D). Treatment with 178 
Glib alone did not have any significant effect on cardiac functional recovery (Figure 3A-D and 179 
4A-D).  180 
 
Coronary Flow Rate 
CFR normalised to chicken embryo heart weight (Table 1 and Figure 5) did not differ between 181 
experimental groups. There was an increase in relative CFR following NaHS treatment during 182 
baseline, prior to ischaemia (Figure 5A).  This increase in relative CFR following NaHS 183 
treatment was maintained post-ischaemia; values for AUC recovery in relative CFR were 184 
significantly greater than controls (Figures 5A and 5B). Here, the effects of NaHS on relative 185 
CFR were not altered when co-administered with Glib (Figures 5A and 5B). Treatment with 186 









The IR protocol yielded a myocardial infarct size of 43.9±4.2 % in control embryo hearts, 188 
which was significantly reduced to 22.7±8.0 % with NaHS treatment prior to ischaemia (Figure 189 
6A). This beneficial effect of NaHS was blocked when NaHS was given with Glib (Figure 6A). 190 
Treatment with Glib itself had no significant impact on infarct size (Figure 6A). 191 
 
Perfusate Analysis 
Relative to controls, values for CK and LDH were significantly lower post-ischaemia in the 192 
NaHS treatment group (Figure 6B and 6C). These benefits of NaHS on ischaemic cardiac injury 193 
were no longer occured when Glib was co-administered (Figures 6B and 6C). Treatment with 194 




In this study, we adapted the isolated Langendorff preparation to study the physiology of 197 
cardiac function during  basal conditions and during IR injury using the chicken embryo heart 198 
in late incubation.  This technology will be useful to isolate the direct effects of adverse 199 
conditions during development on embryonic cardiac function independent of effects on the 200 
maternal and/or placental physiology, highlighting the conceptual advance to the field of early 201 
origins of heart disease and developmental programming.  We also provide novel evidence to 202 





injury and that the mechanism of protection involves opening of myocardial KATP channels, 204 
independent of vsodilator effects of H2S on coronary flow.  205 
 
Infarct size is an established global indication of cardiac cell viability (Zhao & Vinten-Johansen, 206 
2002).  Analysis of infarct size at the end of our protocol shows that treatment with a H2S donor 207 
(NaHS) prior to IR almost halved the extent of infarct size. Therefore, H2S appears to 208 
significantly protect the developing heart from infarction. Moreover, data in the present study 209 
suggest that H2S-mediated infarct protection in the embryonic heart relies on the opening of 210 
KATP channels, given that the NaHS-mediated reduction in infarct size is negated when co-211 
administered with Glib, an antagonist of KATP opening. Perfusate analysis in this study 212 
considered the change in LDH and CK pre- and post-ischaemia. LDH is involved in glucose 213 
metabolism, catalysing the inter-conversion of lactate and pyruvate.  In turn, CK catalyses the 214 
conversion of creatine to phosphocreatine, responsible for ATP transfer and utilization (Danese 215 
& Montagnana, 2016).  When cardiomyocytes are damaged, LDH and CK are released from 216 
the cytoplasm into the bloodstream and utilised as clinical biomarkers for cardiac injury 217 
(Danese & Montagnana, 2016).  In our study, the increase in perfusate concentration in LDH 218 
and CK post-ischaemia in control hearts provides strong biochemical evidence for embryonic 219 
cardiac damage resulting from IR injury. Moreover, our data suggest H2S can protect against 220 
this cardiac injury, with values for LDH and CK significantly lower when NaHS was given 221 
prior to ischaemia. This H2S-mediated cardioprotection appears to rely on opening of KATP 222 
channels, since treatment with both NaHS and the KATP antagonist Glib yielded a level of 223 
cardiac injury equivalent to controls. 224 
 
In addition to these two biochemical measures of cardiac health, our study considered the 225 





including chronotropic (HR) and inotropic (LVDP) function as well as left ventricular 227 
contractility (dP/dtmax) and relaxability (dP/dtmin) were impaired by the IR protocol in control 228 
hearts. By contrast, pre-treatment with NaHS improved the recovery of all variables measured, 229 
indicating that the cardioprotective effects of H2S translate onto a functional level. Our study 230 
also suggests that H2S-mediated protection of embryonic cardiac function depends on the 231 
opening of KATP channels, as co-administration of NaHS with Glib prior to ischaemia 232 
dimnished the functional protection conferred by NaHS. 233 
 
It is established that H2S has vasodilator properties (Bhatia, 2005), an effect confirmed in our 234 
experiment.  The data in the present study showed that CFR, independent of the heart size, 235 
significantly increased during baseline immediately following treatment with NaHS.  Further, 236 
this effect pwersisted after IR.  Increased cardiac perfusion maximises the supply of oxygen 237 
and nutrients to the myocardium. Therefore, it could be argued that the cardioprotective effects 238 
of H2S are due to its vasodilator actions rather than other mechanisms.  However, co-239 
administration of NaHS with Glib did not affect the coronary dilator effects while it prevented 240 
the cardioprotective effects.  Therefore, these data strongly support that the cardioprotective 241 
effects of H2S are due to opening of myocardial KATP channels, independent of effects of NaHS 242 
on coronary flow. The data also suggest that the mechanism underlying the dilator effects of 243 
NaHS on CFR does not involve myocardial KATP channels.  244 
 
Glibenclamide (Glib) is a member of the sulfonylurea family, which blocks KATP channels 245 
(Luzi & Poizza, 1997; Negroni et al. 2007).  In the pacncreatic -cell membrane, Glib reduces 246 
the conductance of the KATP channel and the reduced K+ efflux determines membrane 247 
depolarization and influx of Ca2+ that promotes insulin secretion (Luzi & Poizza, 1997; 248 





Type II diabetes (Luzi & Poizza, 1997; Negroni et al. 2007).  In the adult heart, the actions of 250 
Glib have mixes reviews.  On one hand, blockade of myocardial KATP channels enhances Ca2+ 251 
influx and prolongs action potential duration and myocardial contractility, which has been 252 
deemed harmful, particularly during episodes of ischaemia (Khatib & Boyett, 2003; Negroni 253 
et al. 2007). On the other, studies have decsribed Glib as anti-arrythmogenic with 254 
antifibrillatory effects, associating these cardiac beneficial effects to a reduction in the efflux 255 
of K+ induced by ischaemia (Luzi & Poizza, 1997).  In the present study, administration of Glib 256 
alone prior to IR had no significant effect on all biochemical and functional assays of cardiac 257 
health when compared to controls in the chicken embryo. Our interpretation is that since 258 
cardiac KATP channels are closed at rest and only open when ATP levels fall, such as during 259 
ischaemia (Lu et al. 2008), administration of a drug that inhibits KATP channel opening when 260 
they are already closed prior to ischaemia should have negligible effects. Alternatively, lack of 261 
any effects of Glib on cardiac function in the present study may be because of differences 262 
between the embryonic and adult heart, or due to the mode of administration used.  While a 263 
single bolus dose of Glib was sufficient to offset the actions of NaHS in the chicken embryo 264 
heart when administered together, when Glib was given alone, a bolus dose may have been too 265 
short-lived compared to an infusion to induce any noticeable effects on cardiac function before 266 
or during IR.    267 
 
In the present study, it is interesting that the protective effects of NaHS on indices of systolic 268 
and diastolic cardiac function in the chicken embryo heart were most prominent in the first 30 269 
min post-ischaemia and that this protection on cardiac function disappeared by 60 min of 270 
reperfusion.  Despite this, pre-treatment with NaHS had a significant impact on infarct size, 271 
reducing it by half, when measured two hours after the end of the ischaemic insult. Combined, 272 





reperfusion is important in reducing infarct size.  The limited capacity of NaHS in conferring 274 
protection on cardiac function longer-term may be due to the mode of its administration as a 275 
bolus pre-ischaemia rather than a constant infusion into the perfusate. Most drug regimes in 276 
clinical practice involve single/multiple dose administration rather than a continuous infusion.  277 
While the results of the bolus mode of administration provides proof-of-concept and illustrates 278 
preconditioning against IR, continuous infusion with more conservative doses may confer 279 
longer-term protection on cardiac function as well as infarction, with important implications 280 
for human clinical translation.   281 
 
Episodes of asphyxia or ischaemia occur in embryonic or fetal life and they remain an 282 
unfortunately common clinical concern (Vannucci & Perlman, 1997; Giussani, 2016; Bennet, 283 
2017; Ellery et al. 2018).  Moreover, compromised blood supply to the fetal heart has been 284 
shown to disrupt normal cardiac development and programme an increased risk of hypertension 285 
in the adult offspring (Patterson & Zhang, 2010; Giussani & Davidge, 2013).  Thus, there is 286 
clear clinical relevance to identify interventions that may prevent developmental cardiac 287 
ischaemic injury and an early origin of cardiac dysfunction. In this study, we have adapted the 288 
isolated Langendorff technique to study the chicken embryo heart in late incubation.  The ex 289 
vivo chicken embryo heart model is not only amenable to functional study, but also to 290 
biochemical analysis of cardiac damage and infarct size.  Our discoveries reveal that 291 
supplementation with the endogenous gasotransmitter H2S donor NaHS confers significant 292 
direct protection to the embryonic heart during an IR challenge, independent of the presence 293 
of a mother or a placenta. Further, we have identified the opening of cardiac KATP channels 294 
independent of changes in coronary flow being central to the mechanism underlying H2S-295 
mediated direct cardioprotection. Therefore, supplementation with H2S donors offers potential 296 





in offspring of complicated pregnancy, independent of additional possible effects on the 298 
maternal and/ort placental physiology.  We acknoweldge that techniques, such as 299 
echocardiography and cardiac MRI can offer advantages of studying the embryonic or fetal 300 
heart in vivo.  Further, there is increasing interest in how adverse conditions during fetal 301 
development may affect fetal cardiac function in mammalian pregnancy in relation to 302 
gestational timing, duration and severity (Darby et al.  2020).  Therefore, future studies ought 303 
to investigate different modes and doses of administration of candidate cardioprotective 304 
therapeutic agents, such as H2S donors, during the embryonic or fetal periods not only during 305 
healthy conditions but also in development complicated by suboptimal conditions, such as with 306 
chronic hypoxia, excess glucocorticoid exposure or infection.  Sudies should ideally compare 307 
ex vivo with in vivo techniques to assess embryonic or fetal cardiac function, using different 308 
species with the longterm goal of translating rational therapies to the human clinical condition. 309 
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Figure 1. Summary of the experimental protocol. Hearts were isolated from 19-day old 
chicken embryos and perfused using a Langendorff preparation. Hearts were perfused with 
Krebs-Henseleit bicarbonate buffered solution in a retrograde fashion via the aorta at the 
constant pressure of 40 cmH2O, gassed with O2: CO2 (95% : 5%). A small flexible non-elastic 
balloon made from cling film was inserted into left ventricle via the left atrium. The balloon 
contained distilled water and was connected to a rigid water-filled catheter and a calibrated 
pressure transducer.  Indices of left ventricular function were continuously recorded throughout 
the protocol. After basal recording, a 30 minute global ischaemic challenge was introduced 
followed by 120 minutes of reperfusion. Sodium hydrosulfide (NaHS) and / or glibenclamide 
(Glib) were administered as a bolus at a dose of 1mM 10 minutes prior to onset of ischaemia. 
Perfusate was collected before and after ischaemia to determine concentrations of LDH (lactate 
dehydrogenase) and CK (creatine kinase), two established markers of cardiac injury. At the 
end of the experiment, the heart was sliced and slices were stained with triphenyltetrazolium 
chloride for the measurement of infarct size. 
 
Figure 2. Heart slicer and measurement of infarct size. A, shows a custom made slicer for 
use with the chicken embryo heart; B, shows an example of a mid cardiac section showing 
white infarcted tissue, in contrast to healthy tissue which appears red; C, shows how one can 
filter all healthy tissue using the colour-threshold function in ImageJ; D, shows how to select 
an area of interest; E, shows how the parameters of the colour-threshold function in ImageJ 
could be adjusted so that only infarcted tissue is filtered; F, shows how the area of the infarct 





Figure 3. NaHS treatment improves cardiac chronotropic and inotropic recovery after 
an ischaemic challenge via opening KATP channels. Values are mean ± SD. A, heart rate 
(HR) recovery expressed as a percentage of the pre-ischaemic level; B, area under the curve of 
HR recovery; C, left ventricular developed pressure (LVDP) recovery expressed as a 
percentage of the pre-ischaemic level, and D, area under the curve of LVDP recovery. Groups 
are control (Con, white, n=8), Con with NaHS treatment (Con+NaHS, green, n=8), Con with 
combined treatment of NaHS and glibenclamide (Con+NaHS+Glib, red, n=8), and Con with 
Glib treatment (Con+Glib, blue, n=8). NaHS and / or glibenclamide were administered as a 
bolus at a dose of 1mM 10 minutes prior to onset of ischaemia (arrow). Comparisons were 
assessed for statistical significance using three-way ANOVA (A and C) or two-way ANOVA 
(B and D). If interactions between main factors were significant, the Tukey pot hoc test was 
used to isolate differences: *P<0.05, Con vs. Con+NaHS; †P<0.05, Con+NaHS vs. 
Con+NaHS+Glib.  
Figure 4. NaHS treatment improves cardiac contractility and relaxability after an 
ischaemic challenge via opening KATP channels. Values are mean ± SD. A, The maximum 
first derivatives of the LV pressure (dP/dt max) recovery expressed as a percentage of the pre-
ischaemic level; B, area under the curve of dP/dt max recovery; C, The minimum first derivatives 
of the LV pressure (dP/dt min) recovery expressed as a percentage of the pre-ischaemic level, 
and D, area under the curve of dP/dt min recovery.  Groups are control (Con, white, n=8), Con 
with NaHS treatment (Con+NaHS, green, n=8), Con with combined treatment of NaHS and 
glibenclamide (Con+NaHS+Glib, red, n=8), and Con with Glib treatment (Con+Glib, blue, 
n=8). NaHS and / or glibenclamide were administered as a bolus at a dose of 1mM 10 minutes 
prior to onset of ischaemia (arrow). Comparisons were assessed for statistical significance 





main factors were significant, the Tukey pot hoc test was used to isolate differences: *P<0.05, 
Con vs. Con+NaHS.  
Figure 5. NaHS treatment increases coronary flow rate independent of opening of KATP 
channels. Values are mean ± SD. A, Coronary flow rate (CFR) relative to heart weight (HW); 
B, area under the curve of the relative coronary flow rate. Groups are control (Con, white, n=7), 
Con with NaHS treatment (Con+NaHS, green,  n=7), Con with combined treatment of NaHS 
and glibenclamide (Con+NaHS+Glib, red, n=7), and Con with Glib treatment (Con+Glib, blue, 
n=7).  NaHS and / or glibenclamide were administered as a bolus at a dose of 1mM 10 minutes 
prior to onset of ischaemia (arrow). Comparisons were assessed for statistical significance 
using three-way ANOVA (A) or two-way ANOVA (B).  There were no significant interactions 
between main effects.  
Figure 6. NaHS treatment reduces cardiac injury via opening KATP channels. Values are 
mean ± SD. A, cardiac infarct size expressed as a percentage of total area.  Representative 
images and measurements are also shown; B, relative change from baseline in the concentration 
of creatine kinase (CK) at 0 minutes of reperfusion; C, relative change from baseline in the 
concentration of lactate dehydrogenase (LDH) at 0 minutes of reperfusion. Groups are control 
(Con, n=7-8), Con with NaHS treatment (Con+NaHS, n=8), Con with combined treatment of 
NaHS and glibenclamide (Con+NaHS+Glib, n=7-8), and Con with Glib treatment (Con+Glib, 
n=7). NaHS and / or glibenclamide were administered as a bolus at a dose of 1mM 10 minutes 
prior to onset of ischaemia. Comparisons were assessed for statistical significance using two-
way ANOVA. If interactions between main factors were significant, the Tukey pot hoc test 







Table 1. Biometry and basal cardiac function 
  











Body weight (g) 20.21±3.31 20.37±3.27 19.17±2.31 20.05±1.50 
 








     




4.05±0.85 4.57±2.46 6.77±3.00 3.71±2.38 












dP/dtmin  (mmHg/s) 468.5±116.8 
 
469.0±108.6 432.8±69.9 487.4±142.0 
 








Tau (s) 0.05±0.01 
 
0.06±0.02 0.05±0.02 0.03±0.01 
CFR/HW (ml/min/g) 6.41±1.27 6.17±1.80 6.56±1.49 6.23±2.60 
 
 
Values are mean±SD. Groups are control (Con, n=8), Con with NaHS treatment (Con+NaHS, 
n=9), Con with combined treatment of NaHS and glibenclamide (Con+NaHS+Glib, n=10), and 
Con with Glib treatment (Con+Glib, n=8). NaHS and / or glibenclamide were given as a bolus 
at dose of 1mM. LVEDP, left ventricular end diastolic pressure; LVDP, left ventricular 
developed pressure; dP/dtmax, the maximum first derivative of left ventricular pressure; 
dP/dtmin, the minimum first derivative of left ventricular pressure; CI, left ventricular 
contractility index; Tau, left ventricular relaxation time constant; CFR, coronary flow rate; HW, 









Table 2. Cardiac function post drug treatment prior to ischaemia 
  











     




3.90±1.33 4.13±3.69 4.29±3.42 2.18±1.78 












dP/dtmin (mmHg/s) 437.9±82.9 
 
456.4±174.0 372.8±96.4 435.9±89.7 
 








Tau (s) 0.04±0.01 
 
0.07±0.03 0.06±0.03 0.04±0.02 
CFR/HW (ml/min/g) 6.01±1.56 10.35±4.68 12.29±2.72 5.17±2.09 
 
 
Values are mean±SD. Groups are control (Con, n=8), Con with NaHS treatment (Con+NaHS, 
n=9), Con with combined treatment of NaHS and glibenclamide (Con+NaHS+Glib, n=10), and 
Con with Glib treatment (Con+Glib, n=8). NaHS and / or glibenclamide were given as a bolus 
at dose of 1mM. LVEDP, left ventricular end diastolic pressure; LVDP, left ventricular 
developed pressure; dP/dtmax, the maximum first derivative of left ventricular pressure; 
dP/dtmin, the minimum first derivative of left ventricular pressure; CI, left ventricular 
contractility index; Tau, left ventricular relaxation time constant; CFR, coronary flow rate; HW, 
heart weight. Comparisons were assessed for statistical significance using two-way ANOVA.  
There were only differences in CFR/HW: NaHS effects: p<0.0001; Glib effects: p=0.6162, with 
no interaction between main effects: p = 0.1812. 






